The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

James Van Der Beek Gives Life Update Amid Cancer Journey: 'I Was So Emotionally Lit Up' first appeared on Parade on Aug 9, ...

Diagnostic imaging company RadNet (NASDAQ:RDNT) will be announcing earnings results next tomorrow after market close. Here’s ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Guardant Health earns the No. 12 rank among its peers in the Medical-Services industry group. GeneDx Holdings WGS, Hims & Hers Health HIMS and Stevanato Group STVN are among the top 5 highly rated ...

James Van Der Beek is sharing the subtle colorectal cancer symptom he ignored before his shocking diagnosis. “There wasn’t ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

New research reveals that updated colorectal cancer screening among younger Americans has led to significant increases in local-stage tumor detection and diagnoses.

James Van Der Beek has just woken up from a nap as he hops on a Microsoft Teams call.

Exact Sciences has a multipronged approach to cancer testing. Its flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Its second-largest ...